Open label study of the effect of amantadine on weight gain induced by olanzapine
The purpose of the present paper was to investigate the effects of the dopamine agonist amantadine in those patients with weight gain induced by olanzapine. An open trial was conducted in those patients who gained >3 kg in weight induced by olanzapine use. All subjects were evaluated by weight, b...
Gespeichert in:
| Veröffentlicht in: | Psychiatry and clinical neurosciences 2004-04, Vol.58 (2), p.163-167 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 167 |
|---|---|
| container_issue | 2 |
| container_start_page | 163 |
| container_title | Psychiatry and clinical neurosciences |
| container_volume | 58 |
| creator | BAHK, WON‐MYONG LEE, KYOUNG‐UK CHAE, JEONG‐HO PAE, CHI‐UN JUN, TAEYOUN KIM, KWANG‐SOO |
| description | The purpose of the present paper was to investigate the effects of the dopamine agonist amantadine in those patients with weight gain induced by olanzapine. An open trial was conducted in those patients who gained >3 kg in weight induced by olanzapine use. All subjects were evaluated by weight, body mass index (BMI), the Brief Psychiatric Rating Scale (BPRS), and the Extrapyramidal Symptom Rating Scale (ESRS) before and after the use of amantadine in addition to olanzapine. Twenty‐five of 30 enrolled patients completed the present study. Mean bodyweight and BMI was increased by 6.44 ± 4.42 kg and 5.04 ± 3.47 kg/m2 significantly with olanzapine alone (P |
| doi_str_mv | 10.1111/j.1440-1819.2003.01211.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_57189867</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>57189867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5291-2a8afa64f02ce9f1665d46f6727d8014985da3049cb8a9bb05b9ccb1dc484b8b3</originalsourceid><addsrcrecordid>eNqNkE1v1DAQhi1ERT_gLyBf4JbgsR2vfeCAVoUiVW2R4GyNv9qssskSJ2q3vx6HXQFHfPGM5nnt0UMIBVZDOR82NUjJKtBgas6YqBlwgPrpBTn7M3hZasFFBQLUKTnPecMKKRS8IqfQMGY0hzPy7XYXe9qhix3N0xz2dEh0eog0phT9tHS4xX7C0PaRDj19jO39w0Tvse1p24fZx0BdSXXYP-OuQK_JScIuxzfH-4L8-Hz5fX1VXd9--br-dF35hhuoOGpMqGRi3EeTQKkmSJXUiq-CZiCNbgIKJo13Go1zrHHGewfBSy2dduKCvD-8uxuHn3PMk9222ceuLBKHOdtmBdpotSqgPoB-HHIeY7K7sd3iuLfA7KLTbuxizS7W7KLT_tZpn0r07fGP2W1j-Bs8-ivAuyOA2WOXRux9m__hlFDcyMJ9PHCPbRf3_72AvVvfLJX4BQzyj8o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>57189867</pqid></control><display><type>article</type><title>Open label study of the effect of amantadine on weight gain induced by olanzapine</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Open Access Titles of Japan</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>BAHK, WON‐MYONG ; LEE, KYOUNG‐UK ; CHAE, JEONG‐HO ; PAE, CHI‐UN ; JUN, TAEYOUN ; KIM, KWANG‐SOO</creator><creatorcontrib>BAHK, WON‐MYONG ; LEE, KYOUNG‐UK ; CHAE, JEONG‐HO ; PAE, CHI‐UN ; JUN, TAEYOUN ; KIM, KWANG‐SOO</creatorcontrib><description>The purpose of the present paper was to investigate the effects of the dopamine agonist amantadine in those patients with weight gain induced by olanzapine. An open trial was conducted in those patients who gained >3 kg in weight induced by olanzapine use. All subjects were evaluated by weight, body mass index (BMI), the Brief Psychiatric Rating Scale (BPRS), and the Extrapyramidal Symptom Rating Scale (ESRS) before and after the use of amantadine in addition to olanzapine. Twenty‐five of 30 enrolled patients completed the present study. Mean bodyweight and BMI was increased by 6.44 ± 4.42 kg and 5.04 ± 3.47 kg/m2 significantly with olanzapine alone (P < 0.001). When amantadine and olanzapine were used together, the average weight and BMI decreased by 1.07 ± 3.19 kg and 0.84 ± 2.5 kg/m2, but did not have statistical significance. The average values of BPRS showed a significant decrease (P < 0.001). No significant changes were present in ESRS. Amantadine did not have an effect on weight gain induced by olanzapine. Randomized placebo‐controlled prospective studies are needed.</description><identifier>ISSN: 1323-1316</identifier><identifier>EISSN: 1440-1819</identifier><identifier>DOI: 10.1111/j.1440-1819.2003.01211.x</identifier><identifier>PMID: 15009821</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Ltd</publisher><subject>Adult ; Amantadine ; Amantadine - adverse effects ; Amantadine - therapeutic use ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Benzodiazepines - adverse effects ; Benzodiazepines - therapeutic use ; Biological and medical sciences ; Bipolar Disorder - drug therapy ; Body Mass Index ; Body Weight - drug effects ; Brief Psychiatric Rating Scale ; Depressive Disorder, Major - drug therapy ; Dopamine Agonists - adverse effects ; Dopamine Agonists - therapeutic use ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Drug toxicity and drugs side effects treatment ; Female ; Humans ; Korea ; Male ; Medical sciences ; Middle Aged ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Neurologic Examination - drug effects ; Olanzapine ; Pharmacology. Drug treatments ; Psychotic Disorders - drug therapy ; Schizophrenia - drug therapy ; Treatment ; Treatment Outcome ; Weight gain</subject><ispartof>Psychiatry and clinical neurosciences, 2004-04, Vol.58 (2), p.163-167</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5291-2a8afa64f02ce9f1665d46f6727d8014985da3049cb8a9bb05b9ccb1dc484b8b3</citedby><cites>FETCH-LOGICAL-c5291-2a8afa64f02ce9f1665d46f6727d8014985da3049cb8a9bb05b9ccb1dc484b8b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1440-1819.2003.01211.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1440-1819.2003.01211.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,1435,27931,27932,31007,45581,45582,46416,46840</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15636294$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15009821$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BAHK, WON‐MYONG</creatorcontrib><creatorcontrib>LEE, KYOUNG‐UK</creatorcontrib><creatorcontrib>CHAE, JEONG‐HO</creatorcontrib><creatorcontrib>PAE, CHI‐UN</creatorcontrib><creatorcontrib>JUN, TAEYOUN</creatorcontrib><creatorcontrib>KIM, KWANG‐SOO</creatorcontrib><title>Open label study of the effect of amantadine on weight gain induced by olanzapine</title><title>Psychiatry and clinical neurosciences</title><addtitle>Psychiatry Clin Neurosci</addtitle><description>The purpose of the present paper was to investigate the effects of the dopamine agonist amantadine in those patients with weight gain induced by olanzapine. An open trial was conducted in those patients who gained >3 kg in weight induced by olanzapine use. All subjects were evaluated by weight, body mass index (BMI), the Brief Psychiatric Rating Scale (BPRS), and the Extrapyramidal Symptom Rating Scale (ESRS) before and after the use of amantadine in addition to olanzapine. Twenty‐five of 30 enrolled patients completed the present study. Mean bodyweight and BMI was increased by 6.44 ± 4.42 kg and 5.04 ± 3.47 kg/m2 significantly with olanzapine alone (P < 0.001). When amantadine and olanzapine were used together, the average weight and BMI decreased by 1.07 ± 3.19 kg and 0.84 ± 2.5 kg/m2, but did not have statistical significance. The average values of BPRS showed a significant decrease (P < 0.001). No significant changes were present in ESRS. Amantadine did not have an effect on weight gain induced by olanzapine. Randomized placebo‐controlled prospective studies are needed.</description><subject>Adult</subject><subject>Amantadine</subject><subject>Amantadine - adverse effects</subject><subject>Amantadine - therapeutic use</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Benzodiazepines - adverse effects</subject><subject>Benzodiazepines - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bipolar Disorder - drug therapy</subject><subject>Body Mass Index</subject><subject>Body Weight - drug effects</subject><subject>Brief Psychiatric Rating Scale</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Dopamine Agonists - adverse effects</subject><subject>Dopamine Agonists - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Therapy, Combination</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>Humans</subject><subject>Korea</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Neurologic Examination - drug effects</subject><subject>Olanzapine</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Schizophrenia - drug therapy</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><subject>Weight gain</subject><issn>1323-1316</issn><issn>1440-1819</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNkE1v1DAQhi1ERT_gLyBf4JbgsR2vfeCAVoUiVW2R4GyNv9qssskSJ2q3vx6HXQFHfPGM5nnt0UMIBVZDOR82NUjJKtBgas6YqBlwgPrpBTn7M3hZasFFBQLUKTnPecMKKRS8IqfQMGY0hzPy7XYXe9qhix3N0xz2dEh0eog0phT9tHS4xX7C0PaRDj19jO39w0Tvse1p24fZx0BdSXXYP-OuQK_JScIuxzfH-4L8-Hz5fX1VXd9--br-dF35hhuoOGpMqGRi3EeTQKkmSJXUiq-CZiCNbgIKJo13Go1zrHHGewfBSy2dduKCvD-8uxuHn3PMk9222ceuLBKHOdtmBdpotSqgPoB-HHIeY7K7sd3iuLfA7KLTbuxizS7W7KLT_tZpn0r07fGP2W1j-Bs8-ivAuyOA2WOXRux9m__hlFDcyMJ9PHCPbRf3_72AvVvfLJX4BQzyj8o</recordid><startdate>200404</startdate><enddate>200404</enddate><creator>BAHK, WON‐MYONG</creator><creator>LEE, KYOUNG‐UK</creator><creator>CHAE, JEONG‐HO</creator><creator>PAE, CHI‐UN</creator><creator>JUN, TAEYOUN</creator><creator>KIM, KWANG‐SOO</creator><general>Blackwell Publishing Ltd</general><general>Blackwell Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope></search><sort><creationdate>200404</creationdate><title>Open label study of the effect of amantadine on weight gain induced by olanzapine</title><author>BAHK, WON‐MYONG ; LEE, KYOUNG‐UK ; CHAE, JEONG‐HO ; PAE, CHI‐UN ; JUN, TAEYOUN ; KIM, KWANG‐SOO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5291-2a8afa64f02ce9f1665d46f6727d8014985da3049cb8a9bb05b9ccb1dc484b8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Amantadine</topic><topic>Amantadine - adverse effects</topic><topic>Amantadine - therapeutic use</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Benzodiazepines - adverse effects</topic><topic>Benzodiazepines - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bipolar Disorder - drug therapy</topic><topic>Body Mass Index</topic><topic>Body Weight - drug effects</topic><topic>Brief Psychiatric Rating Scale</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Dopamine Agonists - adverse effects</topic><topic>Dopamine Agonists - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Therapy, Combination</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>Humans</topic><topic>Korea</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Neurologic Examination - drug effects</topic><topic>Olanzapine</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Schizophrenia - drug therapy</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><topic>Weight gain</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BAHK, WON‐MYONG</creatorcontrib><creatorcontrib>LEE, KYOUNG‐UK</creatorcontrib><creatorcontrib>CHAE, JEONG‐HO</creatorcontrib><creatorcontrib>PAE, CHI‐UN</creatorcontrib><creatorcontrib>JUN, TAEYOUN</creatorcontrib><creatorcontrib>KIM, KWANG‐SOO</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><jtitle>Psychiatry and clinical neurosciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BAHK, WON‐MYONG</au><au>LEE, KYOUNG‐UK</au><au>CHAE, JEONG‐HO</au><au>PAE, CHI‐UN</au><au>JUN, TAEYOUN</au><au>KIM, KWANG‐SOO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Open label study of the effect of amantadine on weight gain induced by olanzapine</atitle><jtitle>Psychiatry and clinical neurosciences</jtitle><addtitle>Psychiatry Clin Neurosci</addtitle><date>2004-04</date><risdate>2004</risdate><volume>58</volume><issue>2</issue><spage>163</spage><epage>167</epage><pages>163-167</pages><issn>1323-1316</issn><eissn>1440-1819</eissn><abstract>The purpose of the present paper was to investigate the effects of the dopamine agonist amantadine in those patients with weight gain induced by olanzapine. An open trial was conducted in those patients who gained >3 kg in weight induced by olanzapine use. All subjects were evaluated by weight, body mass index (BMI), the Brief Psychiatric Rating Scale (BPRS), and the Extrapyramidal Symptom Rating Scale (ESRS) before and after the use of amantadine in addition to olanzapine. Twenty‐five of 30 enrolled patients completed the present study. Mean bodyweight and BMI was increased by 6.44 ± 4.42 kg and 5.04 ± 3.47 kg/m2 significantly with olanzapine alone (P < 0.001). When amantadine and olanzapine were used together, the average weight and BMI decreased by 1.07 ± 3.19 kg and 0.84 ± 2.5 kg/m2, but did not have statistical significance. The average values of BPRS showed a significant decrease (P < 0.001). No significant changes were present in ESRS. Amantadine did not have an effect on weight gain induced by olanzapine. Randomized placebo‐controlled prospective studies are needed.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>15009821</pmid><doi>10.1111/j.1440-1819.2003.01211.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1323-1316 |
| ispartof | Psychiatry and clinical neurosciences, 2004-04, Vol.58 (2), p.163-167 |
| issn | 1323-1316 1440-1819 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_57189867 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Applied Social Sciences Index & Abstracts (ASSIA); Open Access Titles of Japan; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
| subjects | Adult Amantadine Amantadine - adverse effects Amantadine - therapeutic use Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Benzodiazepines - adverse effects Benzodiazepines - therapeutic use Biological and medical sciences Bipolar Disorder - drug therapy Body Mass Index Body Weight - drug effects Brief Psychiatric Rating Scale Depressive Disorder, Major - drug therapy Dopamine Agonists - adverse effects Dopamine Agonists - therapeutic use Dose-Response Relationship, Drug Drug Therapy, Combination Drug toxicity and drugs side effects treatment Female Humans Korea Male Medical sciences Middle Aged Miscellaneous (drug allergy, mutagens, teratogens...) Neurologic Examination - drug effects Olanzapine Pharmacology. Drug treatments Psychotic Disorders - drug therapy Schizophrenia - drug therapy Treatment Treatment Outcome Weight gain |
| title | Open label study of the effect of amantadine on weight gain induced by olanzapine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T08%3A43%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Open%20label%20study%20of%20the%20effect%20of%20amantadine%20on%20weight%20gain%20induced%20by%20olanzapine&rft.jtitle=Psychiatry%20and%20clinical%20neurosciences&rft.au=BAHK,%20WON%E2%80%90MYONG&rft.date=2004-04&rft.volume=58&rft.issue=2&rft.spage=163&rft.epage=167&rft.pages=163-167&rft.issn=1323-1316&rft.eissn=1440-1819&rft_id=info:doi/10.1111/j.1440-1819.2003.01211.x&rft_dat=%3Cproquest_cross%3E57189867%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=57189867&rft_id=info:pmid/15009821&rfr_iscdi=true |